Litt’s Drug profile for Sipuleucel-T

Trade Name: Provenge (Dendreon)
Indications: Treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer
Class: Anti-prostate cancer agent, Vaccine
Half-life: N/A

Clinically important, potentially hazardous interactions with:
Abatacept, Alefacept, Azacitidine, Betamethasone, Cabazitaxel, Denileukin, Docetaxel, Fingolimod, Gefitinib, Lenalidomide, Oxaliplatin, Pazopanib, Pemetrexed, Pralatrexate, Triamcinolone

Please login to view the rest of this drug profile.

Page last updated 09/25/2026

Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

Breast feeding

Geriatric

Pediatric